Opdualag, melanoma

BMJ’s Phase III Opdualag study fails to meet endpoints
The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.
Nivolumab/Relatlimab Combo Fails to Meet RFS Endpoint in Melanoma Trial
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.
BMS study of Opdualag in adjuvant melanoma ends in failure
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 study, which enrolled people with stage III-IV melanoma that had been completely surgically removed.
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
Bristol-Myers' Opdualag fails Phase 3 melanoma study
Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing Opdualag,
Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatl
Medscape8d
Advances in Systemic Treatments for Melanoma Highlighted
Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...
Replimune: A Misunderstood Contender In Oncolytics
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
Targeted Oncology1d
Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...
Medscape23d
How New Research Is Redefining Melanoma Treatment
Recent long-term data on pembrolizumab and nivolumab has reaffirmed the benefits of anti-PD-1 therapies in managing residual melanoma. However, Funck-Brentano cautioned, “Most patients do not ...
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...